<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389555</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000436</org_study_id>
    <nct_id>NCT03389555</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial</brief_title>
  <official_title>Ascorbic Ccid, Hydrocortisone, and Thiamine in Sepsis and Septic Shock - A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Open Philanthropy Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aim to determine whether the combination of Ascorbic Acid (Vitamin C),&#xD;
      Thiamine (Vitamin B1), and Corticosteroids improves the trajectory of organ failure and&#xD;
      reduces mortality in patients with sepsis and septic shock as compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis and Septic Shock are common and highly morbid clinical conditions without any specific&#xD;
      therapy aside from antibiotics. A recent quasi-experimental study (Marik et. al., PMID&#xD;
      27940189) demonstrated a remarkable benefit when the combination of Ascorbic Acid (Vitamin&#xD;
      C), Corticosteroids, and Thiamine (Vitamin B1) were given to patients with sepsis. In&#xD;
      particular, patients who received this combination of medications required a shorter amount&#xD;
      of time on vasopressors, suffered less organ failure, and had improved mortality. Vitamin C&#xD;
      has long been suggested for treatment of patients with severe infection as it exerts&#xD;
      significant anti-oxidant effects and reduces endothelial permeability. Corticosteroids, a&#xD;
      mainstay of therapy for refractory shock in sepsis, have also been shown to enhance the&#xD;
      beneficial cellular effects of vitamin C. Finally, thiamine has been shown to be an effective&#xD;
      mitochondrial resuscitator in sepsis, especially for the ~30% of septic shock patients who&#xD;
      present with thiamine deficiency (Donnino et. al, PMID 26771781).&#xD;
&#xD;
      In this study, we aim to reproduce the findings of Marik et. al. using a more rigorous study&#xD;
      design (i.e. a blinded, randomized clinical trial) and focus on the important clinical&#xD;
      outcomes of organ failure and death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">November 26, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours</measure>
    <time_frame>Enrollment to 72-hours</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours. The SOFA score ranges from a minimum of 0 to a maximum of 24, with higher scores meaning worse outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Failure</measure>
    <time_frame>Enrollment until 7-days or discharge from the ICU</time_frame>
    <description>Development of renal failure as defined by a Kidney Disease Improving Global Outcomes [KDIGO] stage 3 or higher. There are 3 stages in the KDIGO scale with stage 3 being the worst (corresponds to renal failure).&#xD;
Stage 1- serum creatinine 1.5 to 1.9 times baseline OR an increase in serum creatinine ≥ 0.3 mg/dL OR urine output &lt; 0.5ml/kg/hour for 6-12 hours. Stage 2- serum creatinine 2.0-2.9 times baseline OR urine output &lt;0.5mg/kg/hour for ≥ 12 hours Stage 3- serum creatinine 3.0 times baseline (or serum creatinine of more than or equal to 4.0 mg/dl with an acute increase of at least 0.5 mg/dl) (OR) Urine output less than 0.3 ml/kg/hour for 24 hours or anuria for 12 hours or new renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>Enrollment until 30-days after enrollment</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>Ventilator free days over the first 7-days after enrollment</time_frame>
    <description>Days not receiving invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Shock Free Days</measure>
    <time_frame>Vasopressor free days over the first 7-days after enrollment</time_frame>
    <description>Days not receiving vasopressor</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU Free Days</measure>
    <time_frame>From enrollment until 28 days after enrollment</time_frame>
    <description>Number of days that the patient was not in the ICU. Timeframe listed below.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>Enrollment until hospital discharge, death, or 30-days. Whichever comes first.</time_frame>
    <description>Hospital mortality rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive Care Unit (ICU) Mortality</measure>
    <time_frame>Enrollment until ICU discharge, death, or 30-days. Whichever comes first.</time_frame>
    <description>ICU mortality rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Delirium</measure>
    <time_frame>On day 3 (at approximately 72 hours) after the first study drug dose</time_frame>
    <description>Describes if patient has delirium as defined by the Confusion Assessment Method (CAM)-ICU. The CAM-ICU method requires that the patient have 3 features to qualify for delirium:&#xD;
Acute Onset of Changes or Fluctuations in the Course of Mental Status (AND )&#xD;
Inattention (AND)&#xD;
Disorganized thinking (OR) Altered Level of Consciousness</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Disposition: Survivors Discharged Home</measure>
    <time_frame>Enrollment until hospital discharge, death, or 30-days, whichever comes first.</time_frame>
    <description>Home hospital disposition in patients who survive to discharge</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Metabolic Disturbance</condition>
  <arm_group>
    <arm_group_label>Vitamin C, Vitamin B1, Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin C, vitamin B1, hydrocortisone</intervention_name>
    <description>Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
    <arm_group_label>Vitamin C, Vitamin B1, Corticosteroids</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
    <other_name>Thiamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline (0.9% NaCl solution) volume to match all components</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patient (age ≥ 18 years)&#xD;
&#xD;
          2. Suspected (cultures drawn and antibiotic given) or confirmed (via culture results)&#xD;
             infection&#xD;
&#xD;
          3. Receiving vasopressor (norepinephrine, phenylephrine, epinephrine, dopamine,&#xD;
             angiotensin II or vasopressin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Member of a protected population (pregnant, prisoner)&#xD;
&#xD;
          2. Known kidney stones within the past 1 year (except for asymptomatic, incidentally&#xD;
             noted stones on imaging)&#xD;
&#xD;
          3. End stage renal disease (ESRD) requiring dialysis&#xD;
&#xD;
          4. Known Glucose-6-Phosphate Dehydrogenase deficiency&#xD;
&#xD;
          5. Known Hemachromatosis&#xD;
&#xD;
          6. Comfort Measures Only status&#xD;
&#xD;
          7. Anticipated death within 24-hours despite maximal therapy (as determined by the&#xD;
             enrolling physician)&#xD;
&#xD;
          8. Receiving supplemental thiamine in a dose greater than that contained in a&#xD;
             multivitamin&#xD;
&#xD;
          9. Clinical indication for steroids (e.g. chronic use) as determined by the clinical team&#xD;
             providing this drug&#xD;
&#xD;
         10. Clinical indication for thiamine as determined by the clinical team providing this&#xD;
             drug&#xD;
&#xD;
         11. Clinical indication for ascorbic acid as determined by the clinical team providing&#xD;
             this drug&#xD;
&#xD;
         12. Known allergy to vitamin C, hydrocortisone, or thiamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Donnino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Auburn Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6.</citation>
    <PMID>27940189</PMID>
  </reference>
  <reference>
    <citation>Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2017 May;14(5):737-741. doi: 10.1513/AnnalsATS.201608-656BC.</citation>
    <PMID>28207287</PMID>
  </reference>
  <reference>
    <citation>Donnino MW, Andersen LW, Chase M, Berg KM, Tidswell M, Giberson T, Wolfe R, Moskowitz A, Smithline H, Ngo L, Cocchi MN; Center for Resuscitation Science Research Group. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016 Feb;44(2):360-7. doi: 10.1097/CCM.0000000000001572.</citation>
    <PMID>26771781</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Donnino</investigator_full_name>
    <investigator_title>Associate Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Metabolic Resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03389555/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03389555/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin C, Vitamin B1, Corticosteroids</title>
          <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin C, Vitamin B1, Corticosteroids</title>
          <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="15.0"/>
                    <measurement group_id="B2" value="67.7" spread="13.9"/>
                    <measurement group_id="B3" value="68.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Excluded 10 patients in intervention arm and 6 patients in placebo arm who did not have race data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, mean (SD)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="10.1"/>
                    <measurement group_id="B2" value="27.9" spread="8.4"/>
                    <measurement group_id="B3" value="28.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History,</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title># with Malignancy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># with Coronary Artery Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># with Congestive Heart Failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Infectious Source</title>
          <population>Patients who did not have an identifiable primary infectious disease source were excluded from these tabulations (7 in intervention and 6 in placebo)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Pneumonia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intra-abdominal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Tract Infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Volume of Intravenous Fluids Prior to Study Drug</title>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2000" lower_limit="1062" upper_limit="3000"/>
                    <measurement group_id="B2" value="2000" lower_limit="1125" upper_limit="3000"/>
                    <measurement group_id="B3" value="2000" lower_limit="1093.5" upper_limit="3000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Vasopressor Initiation to First Study Drug</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="8.1" upper_limit="19.1"/>
                    <measurement group_id="B2" value="13.0" lower_limit="7.5" upper_limit="20.5"/>
                    <measurement group_id="B3" value="13.5" lower_limit="8.0" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Informed Consent to First Study Drug</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.0" lower_limit="1.5" upper_limit="2.7"/>
                    <measurement group_id="B3" value="2.1" lower_limit="1.6" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cardiovascular Component of Total SOFA Score</title>
          <description>Baseline Cardiovascular Component of the Sequential Organ Failure Assessment (SOFA) score: The cardiovascular component of the SOFA score ranges from 0 (best) to 4 (worst), with a score of 0 indicating a mean arterial pressure of ≥ 70 mmHg, a score of 1 indicating a mean arterial pressure of &lt; 70 mmHg, a score of 2 indicating dopamine dosing of ≤ 5 µg/kg/min or any dose of dobutamine, a score of 3 indicating norepinephrine dosing of ≤1mcg/kg/min (or equivalent) and a score of 4 indicating a norepinephrine dose &gt;1mcg/kg/min (or equivalent).</description>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="B3" value="4" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># on Mechanical Ventilation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># with Acute Respiratory Distress Syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>30 Day Predicted Survival</title>
          <description>At time of enrollment, the physician enrolling the patient is asked to predict the patient's chances of survival at the time-point 30 days after enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High Likelihood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncertain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Likelihood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lactate</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                    <count group_id="B2" value="99"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" lower_limit="1.3" upper_limit="2.9"/>
                    <measurement group_id="B2" value="1.8" lower_limit="1.4" upper_limit="2.8"/>
                    <measurement group_id="B3" value="1.8" lower_limit="1.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours</title>
        <description>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours. The SOFA score ranges from a minimum of 0 to a maximum of 24, with higher scores meaning worse outcomes.</description>
        <time_frame>Enrollment to 72-hours</time_frame>
        <population>For the 72 hour SOFA score, patients who expired prior to that time point are excluded from the calculation of mean (SD) of the 72 hour SOFA score.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours</title>
          <description>Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours. The SOFA score ranges from a minimum of 0 to a maximum of 24, with higher scores meaning worse outcomes.</description>
          <population>For the 72 hour SOFA score, patients who expired prior to that time point are excluded from the calculation of mean (SD) of the 72 hour SOFA score.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Enrollment SOFA score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="3.5"/>
                    <measurement group_id="O2" value="9.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hour SOFA score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="4.1"/>
                    <measurement group_id="O2" value="5.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary outcome was analyzed using a linear mixed-effects model where the correlation of within-patient repeated SOFA score measures was accounted for via the use of an unstructured variance-covariance matrix and linear contrasts. Covariates included age, sex, treatment group, time, and the interaction between treatment group and time. Study site was included as a random intercept. The model estimates the mean difference in SOFA score at 72 hours between treatment and control groups.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin: if confidence interval for mean difference between SOFA scores at 72 hour time-point for two groups overlaps 0 (p-value &gt; 0.05) scores considered to be equivalent. Note: The model estimates the mean difference in SOFA score at 72 hours between treatment and control groups, for those patient for whom a SOFA score could be calculated at the 72 hour time point (i.e patients that were alive at the 72 hour time point, 90 patients in the treatment and 88 patients in the control).</non_inferiority_desc>
            <p_value>0.12</p_value>
            <p_value_desc>A priori threshold for significance, p-value &lt; 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Failure</title>
        <description>Development of renal failure as defined by a Kidney Disease Improving Global Outcomes [KDIGO] stage 3 or higher. There are 3 stages in the KDIGO scale with stage 3 being the worst (corresponds to renal failure).&#xD;
Stage 1- serum creatinine 1.5 to 1.9 times baseline OR an increase in serum creatinine ≥ 0.3 mg/dL OR urine output &lt; 0.5ml/kg/hour for 6-12 hours. Stage 2- serum creatinine 2.0-2.9 times baseline OR urine output &lt;0.5mg/kg/hour for ≥ 12 hours Stage 3- serum creatinine 3.0 times baseline (or serum creatinine of more than or equal to 4.0 mg/dl with an acute increase of at least 0.5 mg/dl) (OR) Urine output less than 0.3 ml/kg/hour for 24 hours or anuria for 12 hours or new renal replacement therapy</description>
        <time_frame>Enrollment until 7-days or discharge from the ICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Failure</title>
          <description>Development of renal failure as defined by a Kidney Disease Improving Global Outcomes [KDIGO] stage 3 or higher. There are 3 stages in the KDIGO scale with stage 3 being the worst (corresponds to renal failure).&#xD;
Stage 1- serum creatinine 1.5 to 1.9 times baseline OR an increase in serum creatinine ≥ 0.3 mg/dL OR urine output &lt; 0.5ml/kg/hour for 6-12 hours. Stage 2- serum creatinine 2.0-2.9 times baseline OR urine output &lt;0.5mg/kg/hour for ≥ 12 hours Stage 3- serum creatinine 3.0 times baseline (or serum creatinine of more than or equal to 4.0 mg/dl with an acute increase of at least 0.5 mg/dl) (OR) Urine output less than 0.3 ml/kg/hour for 24 hours or anuria for 12 hours or new renal replacement therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression analysis evaluating the key secondary outcome of kidney failure in treatment group (intervention versus placebo) controlling for treatment site.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>For the key secondary outcome of kidney failure, 200 patients were estimated to provide 94% power, assuming that 30% of participants in the treatment group and 55% in the placebo group would develop kidney failure. If the adjusted risk difference from the logistic regression analysis overlaps 0, there was considered to be no difference between groups</non_inferiority_desc>
            <p_value>0.58</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>20.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Mortality</title>
        <description>Mortality rate</description>
        <time_frame>Enrollment until 30-days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Mortality</title>
          <description>Mortality rate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox Regression controlling for site used to identify hazard ratio for outcome of death for treatment versus intervention group. Null hypothesis is that hazard ratio is 1.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If confidence interval for hazard ratio crosses 0, hazard of death assumed to be equivalent in the two groups.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ventilator Free Days</title>
        <description>Days not receiving invasive mechanical ventilation</description>
        <time_frame>Ventilator free days over the first 7-days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days</title>
          <description>Days not receiving invasive mechanical ventilation</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Quantile regression controlling for site performed to compare treatment and control group's ventilator free days.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the confidence interval for the median difference in ventilator free days between groups crosses 0, the two groups are considered equivalent.</non_inferiority_desc>
            <p_value>&gt;0.99</p_value>
            <method>Quantile Regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Shock Free Days</title>
        <description>Days not receiving vasopressor</description>
        <time_frame>Vasopressor free days over the first 7-days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Shock Free Days</title>
          <description>Days not receiving vasopressor</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Quantile regression controlling for site performed to compare treatment and control group's shock free days.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the confidence interval for the median difference in shock free days between groups crosses 0, the two groups are considered equivalent.</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>Quantile Regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ICU Free Days</title>
        <description>Number of days that the patient was not in the ICU. Timeframe listed below.</description>
        <time_frame>From enrollment until 28 days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days</title>
          <description>Number of days that the patient was not in the ICU. Timeframe listed below.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="3" upper_limit="25"/>
                    <measurement group_id="O2" value="21" lower_limit="4" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Quantile regression controlling for site performed to compare treatment and control group's ICU free days.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the confidence interval for the median difference in ICU free days between groups crosses 0, the two groups are considered equivalent.</non_inferiority_desc>
            <p_value>0.69</p_value>
            <method>Quantile Regression</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Mortality</title>
        <description>Hospital mortality rate</description>
        <time_frame>Enrollment until hospital discharge, death, or 30-days. Whichever comes first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <description>Hospital mortality rate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression analysis evaluating the key secondary outcome of hospital mortality in treatment group (intervention versus placebo) controlling for treatment site..</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the adjusted risk difference from the logistic regression analysis overlaps 0, there was considered to be no difference between groups</non_inferiority_desc>
            <p_value>0.55</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>20.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intensive Care Unit (ICU) Mortality</title>
        <description>ICU mortality rate</description>
        <time_frame>Enrollment until ICU discharge, death, or 30-days. Whichever comes first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit (ICU) Mortality</title>
          <description>ICU mortality rate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression analysis evaluating the key secondary outcome of ICU mortality in treatment group (intervention versus placebo) controlling for treatment site.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the adjusted risk difference from the logistic regression analysis overlaps 0, there was considered to be no difference between groups</non_inferiority_desc>
            <p_value>0.80</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Delirium</title>
        <description>Describes if patient has delirium as defined by the Confusion Assessment Method (CAM)-ICU. The CAM-ICU method requires that the patient have 3 features to qualify for delirium:&#xD;
Acute Onset of Changes or Fluctuations in the Course of Mental Status (AND )&#xD;
Inattention (AND)&#xD;
Disorganized thinking (OR) Altered Level of Consciousness</description>
        <time_frame>On day 3 (at approximately 72 hours) after the first study drug dose</time_frame>
        <population>We were able to assess CAM-ICU delirium on day 3 in only 83 patients from treatment and 76 patients from the control arm (unable to assess for remaining patients due to death or discharge)</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Delirium</title>
          <description>Describes if patient has delirium as defined by the Confusion Assessment Method (CAM)-ICU. The CAM-ICU method requires that the patient have 3 features to qualify for delirium:&#xD;
Acute Onset of Changes or Fluctuations in the Course of Mental Status (AND )&#xD;
Inattention (AND)&#xD;
Disorganized thinking (OR) Altered Level of Consciousness</description>
          <population>We were able to assess CAM-ICU delirium on day 3 in only 83 patients from treatment and 76 patients from the control arm (unable to assess for remaining patients due to death or discharge)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression analysis evaluating the key secondary outcome of occurrence of delirium in treatment group (intervention versus placebo) controlling for treatment site.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the adjusted risk difference from the logistic regression analysis overlaps 0, there was considered to be no difference between groups</non_inferiority_desc>
            <p_value>0.16</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Disposition: Survivors Discharged Home</title>
        <description>Home hospital disposition in patients who survive to discharge</description>
        <time_frame>Enrollment until hospital discharge, death, or 30-days, whichever comes first.</time_frame>
        <population>Population of patients who survived to hospital discharge. 73 patients in the treatment group and 76 patients in the control group survived to hospital discharge..</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C, Vitamin B1, Corticosteroids</title>
            <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Disposition: Survivors Discharged Home</title>
          <description>Home hospital disposition in patients who survive to discharge</description>
          <population>Population of patients who survived to hospital discharge. 73 patients in the treatment group and 76 patients in the control group survived to hospital discharge..</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression analysis evaluating home hospital disposition in survivors to hospital discharge in intervention versus placebo group controlling for treatment site.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the adjusted risk difference from the logistic regression analysis overlaps 0, there was considered to be no difference between groups</non_inferiority_desc>
            <p_value>0.82</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from enrollment to hospital discharge, an average of 13.5 days for all patients</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin C, Vitamin B1, Corticosteroids</title>
          <description>The combination of vitamin C, vitamin B1, hydrocortisone :&#xD;
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days&#xD;
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days&#xD;
Hydrocortisone 50mg every 6 hours x 4-days&#xD;
vitamin C, vitamin B1, hydrocortisone: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components&#xD;
Normal saline: Normal saline (0.9% NaCl solution) volume to match all components</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="101" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="99" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>New Hospital Acquired Infection</sub_title>
                <counts group_id="E1" events="101" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" events="99" subjects_affected="12" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="101" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" events="99" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Ongoing or planned corticosteroid use was the most common exclusion criterion, perhaps eliminating a subset of patients more likely to benefit from corticosteroids. Some patients were discharged alive from the ICU within 96 hours of enrollment; thus, many patients did not receive a full 4 days of study drug</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michae Donnino</name_or_title>
      <organization>Beth Israel Deaconness Medical Center Emergency Department</organization>
      <phone>(617) 754-2882</phone>
      <email>mdonnino@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

